Candel Therapeutics (CADL) News Today $5.25 -0.06 (-1.13%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$5.06 -0.19 (-3.62%) As of 04:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade ...April 3 at 6:21 AM | seekingalpha.comCandel Therapeutics announces publication of Phase 1b trial data on CAN-2409April 2 at 10:38 AM | markets.businessinsider.comCandel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409April 1 at 9:46 AM | proactiveinvestors.comCandel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma PatientsApril 1 at 8:01 AM | globenewswire.comCandel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMIMarch 29, 2025 | proactiveinvestors.comCandel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMIMarch 29, 2025 | proactiveinvestors.comCandel Therapeutics announces final survival data from CAN-2409 trialMarch 27, 2025 | markets.businessinsider.comCandel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trialMarch 26, 2025 | proactiveinvestors.comCandel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) TreatmentMarch 26, 2025 | globenewswire.comCandel Therapeutics (CADL) Expected to Announce Quarterly Earnings on ThursdayMarch 25, 2025 | americanbankingnews.comCandel Therapeutics, IDEA Pharma announce strategic partnershipMarch 20, 2025 | markets.businessinsider.comCandel Therapeutics, Inc. (NASDAQ:CADL) Insider Charles Schoch Sells 5,000 SharesCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) insider Charles Schoch sold 5,000 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $8.83, for a total transaction of $44,150.00. Following the completion of the sale, the insider now directly owns 38,038 shares of the company's stock, valued at approximately $335,875.54. The trade was a 11.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.March 20, 2025 | marketbeat.comSeshu Tyagarajan Sells 31,278 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) StockCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) CTO Seshu Tyagarajan sold 31,278 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $8.82, for a total value of $275,871.96. Following the completion of the transaction, the chief technology officer now owns 85,512 shares in the company, valued at approximately $754,215.84. The trade was a 26.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.March 20, 2025 | marketbeat.comCandel Therapeutics partners with IDEA Pharma on commercialization of lead asset CAN-2409March 20, 2025 | proactiveinvestors.comCandel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409March 20, 2025 | globenewswire.comInsider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 5,000 Shares of StockMarch 20, 2025 | insidertrades.comCandel Therapeutics (CADL) Projected to Post Earnings on ThursdayCandel Therapeutics (NASDAQ:CADL) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comCandel Therapeutics, Inc. (NASDAQ:CADL) is Halter Ferguson Financial Inc.'s 6th Largest PositionHalter Ferguson Financial Inc. grew its position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 123.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 681,334 shares of the company's stock after buying an additionaMarch 19, 2025 | marketbeat.comCandel Therapeutics appoints Jaffee to RABMarch 18, 2025 | msn.comCandel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory BoardMarch 18, 2025 | markets.businessinsider.comCandel Therapeutics appoints cancer immunology expert to research advisory boardMarch 18, 2025 | proactiveinvestors.comCandel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.March 18, 2025 | globenewswire.comCandel Therapeutics (NASDAQ:CADL) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $19.00 price target on shares of Candel Therapeutics in a report on Friday.March 15, 2025 | marketbeat.comCandel Therapeutics Reports Positive Data from Multiple Clinical Trials and Outlines Plans for CAN-2409 and CAN-3110March 15, 2025 | nasdaq.comCandel Therapeutics (CADL) Receives a Buy from Bank of America SecuritiesMarch 15, 2025 | markets.businessinsider.comCandel Therapeutics Reports Positive Clinical Trial ResultsMarch 15, 2025 | tipranks.comCandel Therapeutics (NASDAQ:CADL) Posts Quarterly Earnings Results, Misses Estimates By $0.17 EPSCandel Therapeutics (NASDAQ:CADL - Get Free Report) issued its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.17).March 14, 2025 | marketbeat.comCandel Therapeutics reports Q4 EPS (40c), consensus (23c)March 13, 2025 | markets.businessinsider.comCandel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipelineMarch 13, 2025 | proactiveinvestors.comCandel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate HighlightsMarch 13, 2025 | globenewswire.comOppenheimer & Co. Inc. Purchases Shares of 37,915 Candel Therapeutics, Inc. (NASDAQ:CADL)Oppenheimer & Co. Inc. purchased a new stake in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 37,915 shares of the company's stock, valuedMarch 8, 2025 | marketbeat.comCandel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Up 30.7% in FebruaryCandel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the target of a significant growth in short interest in February. As of February 15th, there was short interest totalling 3,450,000 shares, a growth of 30.7% from the January 31st total of 2,640,000 shares. Based on an average daily trading volume, of 3,950,000 shares, the days-to-cover ratio is presently 0.9 days. Approximately 10.6% of the shares of the stock are sold short.March 5, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for CADL FY2025 Earnings?Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Investment analysts at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for shares of Candel Therapeutics in a research note issued on Wednesday, February 26th. HC Wainwright analyst V. Bernardino now anticipates that the coMarch 1, 2025 | marketbeat.comCandel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMIFebruary 28, 2025 | proactiveinvestors.comCandel Therapeutics (NASDAQ:CADL) Given New $25.00 Price Target at Canaccord Genuity GroupCanaccord Genuity Group lifted their target price on shares of Candel Therapeutics from $20.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday.February 27, 2025 | marketbeat.comCandel Therapeutics price target raised to $25 from $20 at CanaccordFebruary 27, 2025 | markets.businessinsider.comCandel Therapeutics' (CADL) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $19.00 target price on shares of Candel Therapeutics in a research note on Wednesday.February 26, 2025 | marketbeat.comCandel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic DataFebruary 25, 2025 | seekingalpha.comCandel Therapeutics stock rises on positive trial dataFebruary 25, 2025 | in.investing.comCandel Therapeutics announces overall survival data from Phase 2 CAN-2409 trialFebruary 25, 2025 | markets.businessinsider.comCandel stock plunges 20% following Phase 2 data releaseFebruary 25, 2025 | msn.comCandel Therapeutics reports significant survival benefit for pancreatic cancer therapyFebruary 25, 2025 | proactiveinvestors.comCandel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerFebruary 25, 2025 | globenewswire.comCitigroup Begins Coverage on Candel Therapeutics (NASDAQ:CADL)Citigroup started coverage on Candel Therapeutics in a research note on Thursday. They issued a "buy" rating and a $25.00 target price for the company.February 21, 2025 | marketbeat.comCandel Therapeutics initiated with a Buy at CitiFebruary 20, 2025 | markets.businessinsider.comCitigroup Initiates Coverage of Candel Therapeutics (CADL) with Buy RecommendationFebruary 20, 2025 | msn.comCandel Therapeutics: Entering Its Pivotal YearFebruary 20, 2025 | seekingalpha.comCanaccord Genuity Group Begins Coverage on Candel Therapeutics (NASDAQ:CADL)Canaccord Genuity Group began coverage on Candel Therapeutics in a report on Wednesday. They issued a "buy" rating and a $20.00 price objective for the company.February 20, 2025 | marketbeat.comCanaccord Genuity Initiates Coverage of Candel Therapeutics (CADL) with Buy RecommendationFebruary 19, 2025 | msn.comCanaccord starts Candel Therapeutics at Buy on ‘best-in-class’ 2409 potentialFebruary 19, 2025 | markets.businessinsider.com Remove Ads Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address CADL Media Mentions By Week CADL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CADL News Sentiment▼0.160.61▲Average Medical News Sentiment CADL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CADL Articles This Week▼63▲CADL Articles Average Week Remove Ads Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ETNB News Today SNDX News Today MLYS News Today GPCR News Today SYRE News Today ELVN News Today COLL News Today NRIX News Today VIR News Today PAHC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CADL) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CADL Stock Free CADL Stock Alerts